SinoMab BioScience (HKSE:03681) Accounts Receivable : HK$0.00 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. SinoMab BioScience's accounts receivables for the quarter that ended in Dec. 2024 was HK$0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. SinoMab BioScience's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was HK$-0.44.

SinoMab BioScience Accounts Receivable Historical Data

The historical data trend for SinoMab BioScience's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience Accounts Receivable Chart

SinoMab BioScience Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Receivable

Get a 7-Day Free Trial

SinoMab BioScience Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Receivable	Get a 7-Day Free Trial									-	-	-	-	-

SinoMab BioScience Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

SinoMab BioScience Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

SinoMab BioScience's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), SinoMab BioScience's accounts receivable are only considered to be worth 75% of book value:

SinoMab BioScience's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(114.111	+	0.75 * 0	+	0.5 * 0	-	598.098
-	0	-	0)	/	1091.755
=	-0.44

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

SinoMab BioScience Accounts Receivable Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

SinoMab BioScience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG

Website

https://www.sinomab.com

SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.

Executives

Liu Wenyi	2201 Interest of corporation controlled by you
Qiang Jing
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo	2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Hainan Haiyao Co. Ltd.	2101 Beneficial owner
Leung Shui On	2201 Interest of corporation controlled by you
West Biolake Holdings Limited	2101 Beneficial owner
Skytech Technology Limited	2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch	2106 Person having a security interest in shares
Xu Sijia	2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She	2106 Person having a security interest in shares
Apricot Oversea Holdings Limited	2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si	2101 Beneficial owner
Hai Nan Hai Yao Gu Fen You Xian Gong Si	2101 Beneficial owner

SinoMab BioScience Headlines

No Headlines